220 related articles for article (PubMed ID: 35285950)
1. Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Khan AI; Psutka SP; Patil DH; Hong G; Williams MA; Bilen MA; Sekhar A; Kissick HT; Narayan VM; Joshi SS; Ogan K; Master VA
Cancer; 2022 Jun; 128(11):2073-2084. PubMed ID: 35285950
[TBL] [Abstract][Full Text] [Related]
2. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Sharma P; Zargar-Shoshtari K; Caracciolo JT; Fishman M; Poch MA; Pow-Sang J; Sexton WJ; Spiess PE
Urol Oncol; 2015 Aug; 33(8):339.e17-23. PubMed ID: 26094169
[TBL] [Abstract][Full Text] [Related]
3. Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma.
Higgins MI; Martini DJ; Patil DH; Nabavizadeh R; Steele S; Williams M; Joshi SS; Narayan VM; Sekhar A; Psutka SP; Ogan K; Bilen MA; Master VA
Cancer; 2021 Jun; 127(12):1974-1983. PubMed ID: 33760232
[TBL] [Abstract][Full Text] [Related]
4. Postoperative Changes in Skeletal Muscle Mass Predict Survival of Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy.
Fukushima H; Nakanishi Y; Kataoka M; Tobisu KI; Koga F
Clin Genitourin Cancer; 2017 Apr; 15(2):e229-e238. PubMed ID: 27601279
[TBL] [Abstract][Full Text] [Related]
5. Impact of sarcopenia on post-operative outcomes following nephrectomy and tumor thrombectomy for renal cell carcinoma with inferior vena cava thrombus.
Watanabe S; Ishihara H; Takagi T; Kondo T; Ishiyama R; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Ishida H; Tanabe K
Jpn J Clin Oncol; 2021 Apr; 51(5):819-825. PubMed ID: 33558883
[TBL] [Abstract][Full Text] [Related]
6. Low Skeletal Muscle as a Risk Factor for Worse Survival in Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus.
Schmeusser BN; Midenberg E; Palacios AR; Ali AA; Patil DH; Higgins M; Nabavizadeh R; Croll B; Williams M; Sheehy J; Zheng B; Narayan VM; Joshi SS; Ogan K; Psutka SP; Bilen MA; Master VA
Clin Genitourin Cancer; 2023 Aug; 21(4):475-482.e4. PubMed ID: 37210313
[TBL] [Abstract][Full Text] [Related]
7. Preoperative sarcopenia is associated with poor overall survival in pancreatic cancer patients following pancreaticoduodenectomy.
Peng YC; Wu CH; Tien YW; Lu TP; Wang YH; Chen BB
Eur Radiol; 2021 Apr; 31(4):2472-2481. PubMed ID: 32974690
[TBL] [Abstract][Full Text] [Related]
8. Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma.
Aslan V; Kılıç ACK; Sütcüoğlu O; Eraslan E; Bayrak A; Öksüzoğlu B; Tahtacı G; Özdemir N; Üner A; Günel N; Özet A; Yazıcı O
Urol Oncol; 2022 Nov; 40(11):494.e1-494.e10. PubMed ID: 36137881
[TBL] [Abstract][Full Text] [Related]
9. Decreased Skeletal Muscle Mass is Associated with an Increased Risk of Mortality after Radical Nephrectomy for Localized Renal Cell Cancer.
Psutka SP; Boorjian SA; Moynagh MR; Schmit GD; Costello BA; Thompson RH; Stewart-Merrill SB; Lohse CM; Cheville JC; Leibovich BC; Tollefson MK
J Urol; 2016 Feb; 195(2):270-6. PubMed ID: 26292038
[TBL] [Abstract][Full Text] [Related]
10. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy.
Peyton CC; Abel EJ; Chipollini J; Boulware DC; Azizi M; Karam JA; Margulis V; Master VA; Matin SF; Raman JD; Sexton WJ; Wood CG; Spiess PE
Eur Urol Focus; 2020 Jan; 6(1):104-111. PubMed ID: 30206003
[TBL] [Abstract][Full Text] [Related]
11. The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ≤4 cm.
Tappero S; Barletta F; Piccinelli ML; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Parodi S; Dell'Oglio P; Palumbo C; Briganti A; De Cobelli O; Chun FKH; Graefen M; Longo N; Ahyai S; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
Eur Urol Focus; 2023 Sep; 9(5):742-750. PubMed ID: 36906483
[TBL] [Abstract][Full Text] [Related]
12. Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.
Laukhtina E; Pradere B; D'Andrea D; Rosiello G; Luzzago S; Pecoraro A; Palumbo C; Knipper S; Karakiewicz PI; Margulis V; Quhal F; Sari Motlagh R; Mostafaei H; Mori K; Schuettfort VM; Enikeev D; Shariat SF
Minerva Urol Nephrol; 2022 Jun; 74(3):329-336. PubMed ID: 33769012
[TBL] [Abstract][Full Text] [Related]
13. Association Between Sarcopenia and Survival of Patients with Organ-Confined Renal Cell Carcinoma after Radical Nephrectomy.
Lee J; Suh J; Song C; You D; Jeong IG; Hong B; Hong JH; Kim CS; Ahn H
Ann Surg Oncol; 2022 Apr; 29(4):2473-2479. PubMed ID: 34625877
[TBL] [Abstract][Full Text] [Related]
14. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
[TBL] [Abstract][Full Text] [Related]
15. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
[TBL] [Abstract][Full Text] [Related]
16. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.
Laukhtina E; Pradere B; D Andrea D; Rosiello G; Luzzago S; Pecoraro A; Palumbo C; Knipper S; Karakiewicz PI; Margulis V; Quhal F; Sari Motlagh R; Mostafaei H; Mori K; Kimura S; Enikeev D; Shariat SF
Urol Oncol; 2020 Dec; 38(12):936.e7-936.e14. PubMed ID: 32962909
[TBL] [Abstract][Full Text] [Related]
17. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
18. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.
Antoun S; Lanoy E; Iacovelli R; Albiges-Sauvin L; Loriot Y; Merad-Taoufik M; Fizazi K; di Palma M; Baracos VE; Escudier B
Cancer; 2013 Sep; 119(18):3377-84. PubMed ID: 23801109
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
20. Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study.
Ueki H; Hara T; Okamura Y; Bando Y; Terakawa T; Furukawa J; Harada K; Nakano Y; Fujisawa M
Investig Clin Urol; 2022 Jul; 63(4):415-424. PubMed ID: 35796138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
